Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
2017 · New England Journal of Medicine · 5,655 citations
https://doi.org/10.1056/nejmoa1707447
B
Brian T. Hill
Cleveland Clinic(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
784
Papers
19.8K
Citations
51
h-index
188
i10-index
Brian T. Hill is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research & CAR-T cell therapy research. The author has an h-index of 51, co-authored 667 publications.
ORCID: 0000-0001-8781-3327Papers by this author
worksOutcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
2017 · Journal of Clinical Oncology · 173 citations
https://doi.org/10.1200/jco.2017.72.2157
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
2019 · Journal of Clinical Oncology · 94 citations
https://doi.org/10.1200/jco.18.00690
Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy
2019 · Biology of Blood and Marrow Transplantation · 76 citations
https://doi.org/10.1016/j.bbmt.2019.06.036
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
2019 · Cell Death and Disease · 73 citations
https://doi.org/10.1038/s41419-019-2158-0
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
2022 · Journal of Clinical Oncology · 68 citations
https://doi.org/10.1200/jco.21.02698
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat